Nurix Therapeutics Inc reports results for the quarter ended in November - Earnings Summary

Nurix Therapeutics

15/02/2024 22:09

* Nurix Therapeutics Inc  NRIX.OQ  reported a quarterly
adjusted
loss of 77 cents​​ per share for the quarter ended in November,
higher than the same quarter last year, when the company
reported EPS of -87 cents.  The mean expectation of
twelve analysts for the quarter was for a loss of 57 cents per
share. Wall Street expected results to range from $-1.02 to 35
cents per share.
    * Revenue rose 123.5% to $15.16 million from a year ago;
analysts
expected $22.26 million. 
    * Nurix Therapeutics Inc's reported EPS for the quarter was
a loss
of 77 cents​.
    * The company reported a quarterly loss of $41.96 million.
    * Nurix Therapeutics Inc shares had fallen by 10.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Nurix
Therapeutics Inc is $26.50 
This summary was machine generated from LSEG data February 15 at
10:09 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Nov. 30 2023      -0.57          -0.77          Missed
 Aug. 31 2023      -0.76          -0.68          Beat
 May. 31 2023      -0.56          -0.45          Beat
 Feb. 28 2023      -0.87          -0.75          Beat